Impact of Clonal Hematopoiesis on Solid Tumor Progression Following Radiation Therapy
JCO Precision Oncology · 2025-04 · (9)
DOI: 10.1200/po-24-00548 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Precision Oncology, 2025-04. Verfasst von Jacqueline J Tao und 12 weiteren Autor:innen. Beteiligte Einrichtung: Columbia University Medical Center, New York, NY. Hauptthemen laut MEDLINE: Clonal Hematopoiesis, Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
PURPOSE Clonal hematopoiesis (CH) has been shown to adversely affect outcomes in patients with nonhematologic cancers. However, the effects of CH on response to specific treatments, including radiation therapy (RT), are unknown. METHODS We analyzed patients with solid tumors harboring nonpathogenic somatic or germline ATM mutations (n = 144) and FAT1 mutations (n = 270) who received RT and underwent prospective tumor and matched WBC sequencing using the Memorial Sloan Kettering Integrated Mutation Profiling of Actionable Cancer Targets assay. CH variants were detected in blood samples using a well-validated CH variant detection pipeline. We compared irradiated tumor progression in patients with and without CH. Nonpathogenic ATM mutations and FAT1 mutations have previously been shown not to be associated with response to RT. RESULTS The final cohort consisted of 412 patients who underwent 811 total courses of RT. One hundred sixty-one patients (39.1%) had CH; the most frequently mutated genes were DNMT3A (25.6%), PPM1D (6.2%), TET2 (5.8%), and TP53 (5.0%). Fine-Gray competing-risks analysis, with death treated as a competing event, showed no difference in irradiated tumor progression between patients with and without CH (hazard ratio, 1.09 [95% CI, 0.72 to 1.66]; P = .68). Similarly, subanalyses of CH variant allele frequency and CH mutations in putative cancer drivers did not reveal an association with RT response. CONCLUSION We found no difference in irradiated tumor progression between patients with and without CH. Further studies are warranted to examine the potential clinical implications of CH on treatment responsiveness of solid tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Columbia University Medical Center, New York, NY.
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY.
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY.
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY.
ORCID-Profile: Jacqueline J Tao, Pablo Sánchez Vela, Lior Z Braunstein, Nadeem Riaz, Simon N Powell, Larry Norton, Pedram Razavi, Atif J Khan
Förderung
- NCI NIH HHS
Zitieren
APA
Tao, J. J., Setton, J., Sánchez Vela, P., Safonov, A. M., Comen, E. A., Braunstein, L. Z., Reis-Filho, J. S., Riaz, N., Powell, S. N., Levine, R. L., Norton, L., Razavi, P., & Khan, A. J. (2025). Impact of Clonal Hematopoiesis on Solid Tumor Progression Following Radiation Therapy. JCO Precision Oncology. https://doi.org/10.1200/po-24-00548
Vancouver
Tao JJ, Setton J, Sánchez Vela P, Safonov AM, Comen EA, Braunstein LZ, et al. Impact of Clonal Hematopoiesis on Solid Tumor Progression Following Radiation Therapy. JCO Precision Oncology. 2025. doi:10.1200/po-24-00548
BibTeX
@article{Tao2025,
author = {Tao, Jacqueline J and Setton, Jeremy and Sánchez Vela, Pablo and Safonov, Anton M and Comen, Elizabeth A and Braunstein, Lior Z and Reis-Filho, Jorge S and Riaz, Nadeem and Powell, Simon N and Levine, Ross L and Norton, Larry and Razavi, Pedram and Khan, Atif J},
title = {Impact of Clonal Hematopoiesis on Solid Tumor Progression Following Radiation Therapy},
journal = {JCO Precision Oncology},
year = {2025},
number = {9},
doi = {10.1200/po-24-00548}
}
EUVIMED